If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Shield Therapeutics update on U.S. Commercialisation and John Meyer on 5 Resource Stocks
Tim Watts, CEO of Shield Therapeutics #STX provides an update on its plans to commercialise Accrufer® in the USA and talks about their cash position.
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
John Meyer, Mining analyst and partner at SP Angel talks about:
Altus Strategies #ALS
Arc Minerals #ARCM
Empire Metals #EEE
Rio Tinto #RIO
Solgold #SOLG
(Interview starts at 12 minutes 43 seconds)